Compound and method for treatment of diseases and disorders
OwnerAlexander Karimaninventor
Life of this patent
Estimating the term…
Abstract
The disclosed invention generally relates to treatment and/or prevention of symptoms associated with cannabinoid responsive diseases and disorders in subjects in need thereof, as well as the method of administering therapeutically-effective amount of a pharmaceutical compound containing cannabinoids. The disclosed invention further relates to pharmaceutical compounds for treating and/or preventing symptoms associated with said diseases and disorders.
Claims27
A method of treating with reduced adverse psychotropic effect pain, inflammation, mood and motor symptoms associated with psychiatric, autoimmune and neurological diseases and disorders in a subject manifesting one or more of said symptoms,
- the method comprising administering to a subject 0.3 mg or more of a pharmaceutical compound one or more times in 24 hours, comprising of an extract of a Cannabis plant and at least one pharmacologically inactive substance;
- and
- where said extract contains one or more tetrahydrocannabinol (THC) isomers and one or more cannabidiol (CBD) isomers in the ratio of 1 (THC) and 2 (CBD) by mass;
- and
- where said CBD augments the pharmacodynamics of THC in a subject;
- and
- where said compound contains one or more non-cannabinoid components consisting of one or more of the following:
- terpenes;
- sterols;
- triglycerides;
- alkanes;
- squalene;
- tocopherol;
- carotenoids;
- chlorophyll;
- flavonoid;
- glycosides and alkaloids.
A pharmaceutical compound for treating with reduced adverse psychotropic effect pain, inflammation, mood and motor symptoms associated with psychiatric, autoimmune and neurological diseases and disorders in a subject manifesting one or more of said symptoms, comprising of an extract of Cannabis sativa plant and at least one pharmacologically inactive substance;
- and
- where said extract contains one or more tetrahydrocannabinol (THC) isomers and one or more cannabidiol (CBD) isomers in the ratio of 1 (THC) and 2 (CBD) by mass;
- and
- where said CBD augments the pharmacodynamics of THC in a subject;
- and
- where said compound contains one or more non-cannabinoid components consisting of one or more of the following:
- terpenes;
- sterols;
- triglycerides;
- alkanes;
- squalene;
- tocopherol;
- carotenoids;
- chlorophyll;
- flavonoid;
- glycosides and alkaloids.
A pharmaceutical compound for treating with reduced adverse psychotropic effect pain, inflammation, mood and motor symptoms associated with psychiatric, autoimmune and neurological diseases and disorders in a subject manifesting one or more of said symptoms, comprising of an extract of one or more Cannabis species plants and at least one pharmacologically inactive substance;
- and where said compound is packaged in a soft gelatin capsule, where said capsule does not contain lambda-carrageenan, kappa-carrageenan, iota-carrageenan and any mixture of the carrageenans.
Dependencies are inferred from the claim text.